This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Moore KN , Gunderson CC , Sabbatini P , McMeekin DS , Mantia-Smaldone G , Burger RA , Morgan MA , Kapoun AM , Brachmann RK , Stagg R , Farooki A , O'Cearbhaill RE
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
Gynecol Oncol. 2019 Aug;154(2) :294-301
PMID: 31174889 URL: https://www.ncbi.nlm.nih.gov/pubmed/31174889
AbstractOBJECTIVES: The WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first-in-class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RPh2) for IPA in combination with taxane and platinum therapy (C/P). METHODS: Dose escalation started with a standard 3+3 design for IPA/C/P with q3w intravenous IPA on Day 1, in cycles 1 to 6 with C (AUC=5mg/ml.min) and P (175mg/m(2)). For enhanced bone safety the trial was revised to 6-patient cohorts with a q3w regimen of IPA on Day 1 and C/P on Day 3 (IPA-->C/P). RESULTS: 37 patients have been treated; 30 of whom were treated following protocol revision to q3w IPA(D1)-->C/P(D3) (2 & 4mg/kg). IPA-related TEAEs that occurred in >/=15% included: fatigue (40%); nausea (35%); diarrhea and decreased appetite (22%) each; dysgeusia (19%); and vomiting (16.2%). 22% reported >/=1 IPA related TEAE Grade >/=3 the most common of which was neutropenia at 16%. There were no DLTs; the MTD was not reached. The maximum administered dose based on bone safety was 6mg/kg. The overall response rate (ORR) was 75.7%. Median PFS was 10.3months (95% CI 8.5-14.2) and OS 33months (95% CI 23.4-NR). CONCLUSIONS: IPA is well tolerated in combination with sequential C/P. ORR, PFS and OS are comparable to historical data but bone toxicity at efficacy doses of this particular Wnt inhibitor limit further development in EOC.
Notes1095-6859 Moore, Kathleen N Gunderson, Camille C Sabbatini, Paul McMeekin, D Scott Mantia-Smaldone, Gina Burger, Robert A Morgan, Mark A Kapoun, Ann M Brachmann, Rainer Karl Stagg, Robert Farooki, Azeez O'Cearbhaill, Roisin E P30 CA008748/CA/NCI NIH HHS/United States Journal Article United States Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4.